Physician profile
Jerry Ramos
NPI 1588706600
$7,859.31
in general payments reported to CMS, 2019-2025
25 companies · $221 in 2025
The $221 reported for 2025 was more than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,380 · 2020: $1,025 · 2021: $1,625 · 2022: $1,526 · 2023: $907 · 2024: $176 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,300 · Travel and Lodging: $3.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,299.72 |
| Travel and Lodging | $3.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,435.97 | 2019-2023 | Ozempic, Rybelsus |
| Abbvie INC. | $1,103.83 | 2021-2024 | |
| Astrazeneca Pharmaceuticals Lp | $784.62 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $742.19 | 2019-2023 | Jardiance, Mounjaro |
| Janssen Pharmaceuticals, INC | $576.81 | 2019-2022 | |
| Pfizer INC. | $389.81 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $385.54 | 2019-2023 | Jardiance |
| Allergan, INC. | $382.67 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $338.36 | 2021-2023 | |
| Amarin Pharma, INC. | $333.85 | 2019-2022 | |
| Glaxosmithkline, LLC. | $307.90 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $229.92 | 2019-2023 | Rexulti |
| Amgen INC. | $214.48 | 2019-2025 | Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $180.12 | 2019-2022 | |
| Abbott Laboratories | $91.18 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $78.87 | 2019 | |
| Avanir Pharmaceuticals, INC. | $66.65 | 2019 | |
| Merck Sharp & Dohme LLC | $48.38 | 2019-2021 | |
| Exact Sciences Corporation | $35.25 | 2023 | Cologuard Collection Kit |
| Boston Scientific Corporation | $35.19 | 2024 | |
| Arbor Pharmaceuticals, INC. | $27.82 | 2019 | |
| Eisai INC. | $21.56 | 2022 | |
| Nevro Corp. | $20.45 | 2023 | Senza |
| Kowa Pharmaceuticals America, INC. | $15.22 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Ramos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.